3.229.124.74
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Musculoskeletal/Rheumatology
Trending Topics

Keros Therapeutics Closes $56 Million Series C Financing to Advance its Programs in Hematologic and Musculoskeletal Disorders

Posted on March 7, 2020

Keros Therapeutics, Inc, a biotechnology company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need, announced the close of its $56 million Series C financing, bringing its total venture funding to $78.5 million to date. The Series C financing was led by new investors Foresite Capital, OrbiMed, Cowen Healthcare Investments and Venrock. Certain of Keros’ existing investors also participated including Pontifax, Arkin Bio VenturesPartners Innovation Fund, Global Health Sciences Fund and Medison Pharma.

Proceeds from this financing will be used to advance Keros’s pipeline of product candidates through multiple clinical data readouts. KER-050, our lead clinical-stage protein therapeutic product candidate, is currently being developed to correct cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. KER-047, our lead clinical-stage small molecule product candidate, is being developed for treatment of anemias resulting from high hepcidin levels and for fibrodysplasia ossificans progressiva, or FOP, a rare genetic disease where muscle and connective tissues gradually become replaced by bone.

Read the full press release here.

Source: Keros Therapeutics press release
-Advertisement-
Related Articles
Orthopedic Surgeons Prescribe Less Opioids in States with Access to Medical Cannabis
Mar 21, 2020
Difficulties in Recognizing, Diagnosing Chronic Recurrent Multifocal Osteomyelitis
Mar 20, 2020
Preclinical Data Supporting Tolerability and Activity of Low-dose Infigratinib in Treating Achondroplasia Presented at ASHG 2019 Annual Meeting
Mar 15, 2020
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-